Integrative Analysis of Large-cell Lung Cancer (LCLC)

Tongji University

Status: Enrolling

Conditions: Lung Cancer

Treatments: Other: Normal lung tissue

Study type: Observational

Funder types: Other

Identifiers

NCT02917369

2016-52-Rainy

Details and patient eligibility

About

Integrative analysis of LCLC

Full description

The investigators will analyzed proteomes of paired normal lung tissues and LCLC with or without liver metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary LCLC carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≤ 75 years with histologically proven LCLC
• No severe major organ dysfunction
• World Health Organization (WHO) performance status of 0 or 1
• No prior cancer chemotherapy

Exclusion criteria

• Age ≥ 76
• Severe major organ dysfunction
• WHO performance status of >1
• Prior cancer chemotherapy

Trial design

1,000 participants in 3 patient groups

Normal lung tissue

Description:

Normal lung tissue from LCLC patients

Treatment:

Other: Normal lung tissue

LCLC tissues

Description:

LCLC tissues from LCLC patients

Treatment:

Other: Normal lung tissue

Metastasis tissues

Description:

Metastasis tissues from LCLC patients

Treatment:

Other: Normal lung tissue